News
Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.
Zacks Investment Research on MSN1d
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & MoreMergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to ...
Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to acquire Inozyme Pharma INZY. Meanwhile, other pipeline and ...
Novavax is undervalued, presenting an attractive risk-reward profile for long-term investors. Click here to find out why NVAX ...
BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The ...
The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback